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Adult-onset autosomal-dominant leukodystrophy (ADLD) is a progressive and fatal neurological disorder 
characterized by early autonomic dysfunction, cognitive impairment, pyramidal tract and cerebellar dysfunc-
tion, and white matter loss in the central nervous system. ADLD is caused by duplication of the LMNB1 gene, 
which results in increased lamin B1 transcripts and protein expression. How duplication of LMNB1 leads 
to myelin defects is unknown. To address this question, we developed a mouse model of ADLD that overex-
presses lamin B1. These mice exhibited cognitive impairment and epilepsy, followed by age-dependent motor 
deficits. Selective overexpression of lamin B1 in oligodendrocytes also resulted in marked motor deficits and 
myelin defects, suggesting these deficits are cell autonomous. Proteomic and genome-wide transcriptome stud-
ies indicated that lamin B1 overexpression is associated with downregulation of proteolipid protein, a highly 
abundant myelin sheath component that was previously linked to another myelin-related disorder, Pelizaeus-
Merzbacher disease. Furthermore, we found that lamin B1 overexpression leads to reduced occupancy of Yin 
Yang 1 transcription factor at the promoter region of proteolipid protein. These studies identify a mechanism 
by which lamin B1 overexpression mediates oligodendrocyte cell–autonomous neuropathology in ADLD and 
implicate lamin B1 as an important regulator of myelin formation and maintenance during aging.
Introduction
Myelin defects are characteristic of both common sporadic neuro-
logical diseases such as MS and rare genetic diseases such as adult-
onset autosomal-dominant leukodystrophy (ADLD). Investigation 
of rare inherited diseases whose pathologic features overlap with 
common syndromes often casts light on critical features of com-
mon disorders. Leukodystrophies are a heterogeneous group of rare, 
usually genetic, disorders characterized by white matter pathologies. 
ADLD is a progressive and fatal neurological disorder with onset 
typically in the fourth or fifth decade of life. ADLD is characterized 
by early autonomic dysfunction and cognitive impairment, followed 
by pyramidal tract and cerebellar impairments, and loss of white 
matter in the brain and spinal cord on magnetic resonance imag-
ing. ADLD is often misdiagnosed as chronic progressive MS in its 
initial phases. ADLD is caused by duplication of the LMNB1 gene, 
resulting in increased lamin B1 transcripts and protein expression 
(1). The links between lamin B1 overexpression and demyelination 
are not understood. Improved understanding of ADLD pathogen-
esis holds the promise of providing insights into more common 
sporadic white matter pathologies.
Myelin is a lipid-enriched specialized membrane synthesized by 
oligodendrocytes in the CNS and Schwann cells in the peripheral 
nervous system (2). Myelin wraps around axons, leading to a substan-
tial increase in axonal conductance. Defects in myelin disrupt axo-
nal function and lead to axonal degeneration, although the precise 
mechanisms are not known (2). Several proteins, such as myelin basic 
protein, myelin-associated glycoprotein, and proteolipid protein 
(PLP), are either restricted to, or highly enriched in, the myelin mem-
brane (3). Mutations of the X-linked PLP1 gene encoding PLP, the 
most abundant protein of the CNS myelin sheath, cause Pelizaeus-
Merzbacher disease (PMD), another rare leukodystrophy (4). Muta-
tions in PLP1 ultimately result in the loss or reduction of PLP in the 
myelin sheath. PMD patients and rodent models of PMD show loss 
of white matter and axonal degeneration, indicating that the integ-
rity of the myelin-axon unit is highly sensitive to deficits in PLP (5–8).
Lamins are intermediate filament proteins lining the inner 
nuclear membrane and distributed throughout the nucleoplasm. 
There are 2 major mammalian lamin types, lamin A and B. A-type 
lamins are derived from the LMNA gene through alternative 
splicing, giving rise to 2 isoforms, A and C. B-type lamins, B1 
and B2, are encoded by different genes (LMNB1 and LMNB2) (9, 
10). The nuclear lamina is implicated in a wide range of human 
diseases collectively known as laminopathies (11, 12). Numerous 
functions are ascribed to nuclear lamina, including docking sites 
for chromatin, regulation of gene expression, and nuclear stabil-
ity (13, 14). Lamin B1 is known to maintain nuclear integrity and 
mediate transcriptional regulation (15–17).
We now report a BAC-mediated transgenic approach to gener-
ating a BAC transgenic mouse model of ADLD (Lmnb1BAC). This 
approach allows the advantage of expressing full-length lamin B1 
murine homolog (Lmnb1) under the control of endogenous lamin 
B1 promoter and regulatory sequences. Lmnb1BAC mice recapitu-
lated many of the features of ADLD. In addition, we generated a 
series of transgenic mice overexpressing Lmnb1 in specific CNS cell 
lineages. Our findings indicate that overexpression in oligoden-
drocytes is sufficient for the onset of histopathological, molecu-
lar, and behavioral deficits characteristic of ADLD. As in ADLD, 
pathophysiological effects become evident in adult animals and 
progressively worsen with age. Using Lmnb1BAC mice as the starting 
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point for transcriptome and proteomic profiling, we discovered 
that PLP is downregulated in these animals and that the transcrip-
tional occupancy of Yin Yang 1 (YY1), a transcriptional activator of 
Plp1 (18), is reduced. These results provide a potential link between 
lamin B1 overexpression and PLP downregulation. Together, our 
findings reveal a valid in vivo model for investigation of how aging 
and genetic predispositions can cause myelin defects with devas-
tating effects on health and behavior.
Results
Generation of an ADLD mouse model. To investigate the patho-
physiological mechanism of lamin B1 overexpression in ADLD, 
we generated BAC transgenic mice carrying additional copies of 
murine WT lamin B1 (Lmnb1BAC). To maintain the regulatory 
properties of the endogenous Lmnb1 gene, we made use of large 
genomic fragments containing the entire Lmnb1 locus within 
the BAC. A genomic insert containing Lmnb1 (Figure 1A) was 
isolated from a mouse BAC genomic library. We generated 2 
BAC transgenic lines containing varying numbers of the entire 
Lmnb1 locus. We performed expression analyses of lamin B1 by 
Western blot and quantitative real-time PCR (qRT-PCR) from 
hemibrains of 12-month-old Lmnb1BAC animals. Western blot 
analysis of Lmnb1BAC transgenic animals showed approximately 
4- (line no. 1) and 2.5-fold (line no. 2) higher expression com-
pared with WT littermates (Figure 1, B and C). Consistent with 
protein expression results, the highest transcript levels were 
also found in line no. 1; Lmnb1 mRNA showed approximately 
3.5- (line no. 1) and 1.5-fold (line no. 2) higher expression com-
pared with WT (Figure 1D). Consequently, all of the following 
experiments were performed on line no. 1, the highest express-
ing line. Both transgenic lines with lamin B1 duplication were 
born healthy and indistinguishable from control littermates. 
Line no. 2 progressed with a milder and later onset phenotype 
compared with line no. 1. Line no. 2 did not exhibit any abnor-
mal pathology up to 12 months of age.
ADLD mouse model exhibits cognitive impairment and age-dependent 
motor deficits. Cognitive and motor deficits are both observed in 
ADLD patients. We performed Morris water maze (MWM) and 
passive avoidance (PA) tasks in Lmnb1BAC and WT mice to assess 
cognitive impairments at 12 months and accelerated rotarod and 
balance beam to measure motor deficits at 12 and 24 months 
of age. The MWM is an established paradigm for testing spatial 
memory in rodents (19–21). Lmnb1BAC mice exhibited substantial 
spatial memory deficits in an MWM assay compared with WT 
controls. WT mice exhibited a preference for the target quadrant 
where the platform was located during training compared with 
other quadrants (Figure 2A), indicating that they remembered 
the overall location of the platform. In contrast, Lmnb1BAC mice 
were impaired and did not spend more time in the target quad-
rant compared with others (Figure 2A). Analyses of virtual plat-
form crossings during the probe test revealed that WT animals 
showed a clear preference for the target platform location (Figure 
2B). Nonselective preferences for the target platform by Lmnb1BAC 
mice indicate that they do not recall the location of the hidden 
platform and are impaired in spatial memory retention (Figure 
2B). Lmnb1BAC and WT animals performed equally well during the 
visible platform test and exhibited equal velocities, demonstrating 
that Lmnb1BAC animals were not visually impaired and that neither 
their cued reference memory nor their swimming was impaired 
(data not shown). In agreement with these findings, Lmnb1BAC 
mice exhibited impairments in a step-through PA task, which 
reflects long-term spatial associative learning and fear memory of 
an aversive experience. WT but not Lmnb1BAC mice showed sub-
stantial increase in the latency to avoid the light and step through 
Figure 1
Generation of Lmnb1BAC mice. (A) Map of the genomic insert in the 
BAC RP23-460J18 clone (RPCI library, C57BL/6J) used to gener-
ate mice with increased dosage of lamin B1 (Lmnb1BAC mice). The 
genomic insert is 177.20-kb long and contains the entire Lmnb1 locus. 
Black boxes represent lamin B1–coding sequences, and light gray 
lines indicate the BAC vector (pBACe3.6) sequence. Primers used 
for detection of the transgene are shown (T7 side: F1R1; SP6 side: 
F2, R2). (B) Representative Western blot of lamin B1 and α-tubulin 
in hemibrain lysates from Lmnb1BAC lines and WT mice at 12 months 
of age. (C) Quantification of Western blots normalized to α-tubulin. 
(D) qRT-PCR of lamin B1 transcript levels normalized to GAPDH 
from corresponding Lmnb1BAC mice hemibrains. Error bars represent 
mean ± SEM from 4 independent experiments.
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the dark chamber where they received an electric shock the day 
before (P < 0.01) (Figure 2C). This indicated that Lmnb1BAC mice 
have spatial associative memory deficits compared with WT mice 
at 12 months of age. During training, the latencies to step through 
the dark chamber were not different among genotypes, indicating 
that all the mice showed the same level of spontaneous aversion 
to light. Together, these studies suggest cognitive and memory 
impairments in Lmnb1BAC mice.
Lmnb1BAC animals exhibited progressive motor impairment on 2 
different motor tasks, the accelerated rotarod and balance beam. 
The accelerated rotarod did not detect significant motor impair-
ments at 12 months of age in Lmnb1BAC mice compared with WT. 
However, by 24 months of age, Lmnb1BAC mice were not able to 
remain on the rotarod as long as their WT counterparts (Figure 
2D). The balance beam, typically a more sensitive test for gait 
impairment, detected gait deficits at 12 months and progressed 
to 24 months of age. Lmnb1BAC mice showed increased latency and 
number of hind limb slips to traverse a 42-cm beam that was 5 mm 
in diameter (Figure 2, E and F). Together, these data demonstrate 
age-dependent motor deficits in Lmnb1BAC animals.
Lamin B1 overexpression results in seizures in ADLD mice. Recent 
studies report epilepsy in some patients with myelin diseases, 
including MS and inherited leukodystrophies such as PMD (22, 
23). Murine models of some leukodystrophies exhibit epilepsy 
(24). In addition, some ADLD patients exhibit epilepsy (unpub-
lished observations, Eric Huang). We observed frequent behav-
ioral seizures in Lmnb1BAC animals, which varied from generalized 
spasms and tremors to generalized clonic activity with atonia 
and tail extension. To confirm these observations, we used EEG 
recording. Cortical EEG recordings revealed frequent spontane-
ous epileptic activity, including epileptiform discharges and sei-
zures, in Lmnb1BAC mice but not in WT controls. Representative 
traces over 2 minutes, 30 seconds, of a 24-hour recording showed 
that Lmnb1BAC mice, but not WT mice, displayed frequent interic-
tal spikes (arrowheads) in both left and right hemispheres (Figure 
3A). Lmnb1BAC mice exhibited an approximately 20-fold increase 
in the number of interictal spikes compared with WT mice (Fig-
ure 3B). Given a subconvulsive dose of pentylenetetrazol (PTZ), 
a GABAA receptor antagonist, Lmnb1BAC animals were more sus-
ceptible to PTZ-induced seizures compared with WT controls. 
Seven out of nine Lmnb1BAC animals exhibited seizures within 5 to 
7 minutes of drug administration compared with only 1 out of 9 
WT animals (Figure 3C). These findings demonstrate that lamin 
B1 overexpression induces aberrant brain network activity, such as 
neuronal hypersynchrony and hyperexcitability, and predisposes 
animals to epilepsy.
Lamin B1 overexpression results in aberrant myelin formation, axo-
nal degeneration, and demyelination. To address whether lamin B1 
overexpression is associated with myelin pathology, we examined 
myelin integrity by electron microscopy in 12- and 24-month-old 
Lmnb1BAC and WT mice. Because pathologic studies show greatest 
loss of white matter in pyramidal tracts of ADLD patients (25), 
we performed ultrastructural analysis on pyramidal tracts in the 
brain region of the pons. Although these ultrastructural analyses 
did not identify overall demyelination in 12-month-old animals 
assessed by g ratio (the ratio between the diameter of the inner 
axon and the total outer diameter [Figure 4, A and B]), they did 
identify such demyelination, however, by 24 months compared 
with WT controls (Figure 4, C and D). Ultrastructural analyses 
reveal a variety of aberrant structures, which were generally domi-
Figure 2
A mouse model of ADLD exhibited cognitive and motor deficits. Lmnb1BAC 
and WT mice were behaviorally tested to assess spatial and fear memory 
in the MWM and PA tests and motor functions in the rotarod and balance 
beam tests. (A and B) Lmnb1BAC mice exhibited spatial memory deficits 
in the MWM at 12 month of age. (A) Lmnb1BAC mice spent substantially 
less time in the target quadrant and (B) made less platform area cross-
ings compared with WT during the probe trial. (C) Lmnb1BAC mice failed 
to recall an aversive experience made on the previous day on the PA 
test and exhibited decreased step-through latencies compared with WT 
mice at 12 months of age. The bars indicate the mean latencies to enter 
the dark compartment on the training day (white) and 24 hours later on 
the retention day (black). (D–F) Progressive deterioration of motor func-
tions in Lmnb1BAC mice compared with WT mice, (D) Lmnb1BAC mice 
spent less time on the accelerated rotarod across all 8 trials at 24 but 
not at 12 months of age compared with WT. (E) Lmnb1BAC mice showed 
increased latency to traverse a 5-mm–wide balance beam at 12 months 
and progressively worsened at 24 month. (F) Lmnb1BAC mice also exhib-
ited increased hind limb slips compared with WT controls. Values are 
expressed as mean ± SEM. n = 10–14 per genotypic group. *P < 0.05; 
**P < 0.01; ***P < 0.001.
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nated by outfoldings, extensions, and invaginations originating 
from the myelin sheath. Aberrant myelin loops consisted of multi-
ple loops within the same myelinated axon, which may result from 
a retrograde inversion of a single infolding, since axonal material 
can be seen in the gap between the inner and outer infoldings 
(Figure 4, F and G, 12-month-old animals; Figure 4H, 24-month-
old Lmnb1BAC animals). These morphological abnormalities were 
not seen in WT mice (Figure 4, E and Q, 12 and 24-month-old ani-
mals, respectively). Apart from these abnormalities of the myelin 
sheath, axonal disintegration and even degradation of the entire 
axon-myelin unit was observed at a significantly higher level com-
pared with that in WT controls (Figure 4, I and J, 12-month-old 
animals; Figure 4, M and N, 24-month-old animals). Additionally, 
hypermyelinated fibers (Figure 4, K and L, 12-month-old animals) 
were also observed. Frequent dying and degenerating oligoden-
drocytes were also noted in the 24-month-old Lmnb1BAC animals 
(Figure 4P), which corresponded with demyelinated axons (Fig-
ure 4R) compared with WT controls (Figure 4, O and Q). Tolu-
idine blue staining of adjacent sections showed similar find-
ings of demyelination and aberrant structures in 24-month-old 
Lmnb1BAC animals (Supplemental Figure 1; supplemental mate-
rial available online with this article; doi:10.1172/JCI66737DS1). 
Quantification of approximately 150 to 200 axons for each group 
at 12 months of age showed significant axonal degeneration and 
aberrant myelin formation in Lmnb1BAC animals compared with 
WT controls (Figure 4, S and T), similar to observations found 
in some other myelin disorders (26–28). Because inflammation is 
seen in active MS lesions, we additionally assessed Iba1 and GFAP 
immunostaining for microglia activation and reactive astrocytes, 
respectively, in various regions of the brain, including cortex, 
hippocampus, and cerebellum in 12-month-old Lmnb1BAC and 
control animals. There were no differences in the cortex (Supple-
mental Figure 2), hippocampus, or cerebellum (data not shown). 
These data are consistent with ADLD patient data showing no 
obvious inflammation.
Lamin B1 overexpression induces cell-autonomous neuropathology in 
oligodendrocytes. An interesting feature of ADLD is specific demy-
elination in the presence of ubiquitously overexpressed lamin 
B1 protein. To investigate the pathologic consequences of lamin 
B1 overexpression on different cell lineages in the brain, we 
overexpressed a FLAG-tagged lamin B1 selectively in oligoden-
drocytes, neurons, and astrocytes driven by cell-specific promot-
ers (Plp1, Camk2a, and GFAP, respectively). Each of these lines 
showed expression levels of lamin B1 that were similarly higher 
than their WT counterparts, which were quantified by Western 
blot analyses and qRT-PCR at 12 months of age (Figure 5, A–C). 
Western blot analysis of total lamin B1 showed on average a 2.2-, 
2.4-, and 2.3-fold increase in mice where Lmnb1 was driven by Plp1, 
Camk2a, and GFAP, respectively, compared with WT controls (Fig-
ure 5, A and B). Overexpression levels were consistent with what 
was observed in ADLD patients, which exhibit on average a 2-fold 
increase (1, 11). For reasons we do not completely understand, 
endogenous lamin B1 appeared to increase as a result of lamin B1 
overexpression compared with WT controls (Supplemental Figure 
3A). mRNA by qRT-PCR analyses also exhibited marked and com-
parable increases in all 3 cell-specific lines (Figure 5C). Only ani-
mals overexpressing lamin B1 in oligodendrocytes (PLP-LMNB1Tg) 
exhibited age-dependent motor deficits beginning at 10 months 
(observed) and rapidly progressing to 12 months of age, at which 
time these animals became moribund. At 5 months, PLP-LMNB1Tg 
animals showed no differences on the accelerated rotarod or on an 
11-mm–wide balance beam compared with WT controls (Figure 
5, D–F). However, by 12 months, PLP-LMNB1Tg animals exhibited 
considerable decreased latency to fall on the accelerated rotarod 
(Figure 5D) and showed marked increased latency to traverse the 
balance beam compared with WT controls (P < 0.001) (Figure 5E). 
Additionally, PLP-LMNB1Tg animals exhibited more hind limb slips 
(Figure 5F). These motor deficits observed in the PLP-LMNB1Tg 
mice were accompanied by demyelination, aberrant myelin forma-
tion, and axonal degeneration (Figure 6, B–D). Among aberrant 
myelin loops in PLP-LMNB1Tg animals, myelin-axon structure was 
also irregular and nonuniform compared with WT controls (Fig-
ure 6, E and F). Interspersed within areas of demyelinated axons 
(e.g., Figure 6E, arrow) were axons with normal myelin thickness 
(e.g., Figure 6E, arrowhead). The heterogeneity of myelin thick-
nesses is represented by the g ratio (Figure 6B). WT controls did 
not exhibit demyelination or display aberrant myelin loops (Figure 
6, A and F). Toluidine blue staining of adjacent sections showed 
similar findings of demyelination and aberrant structures in 
Figure 3
Lamin B1 overexpression results in seizures. Spontaneous EEG activ-
ity over the parietal cortex of Lmnb1BAC and WT mice was recorded 
for 24 hours. (A) EEG recordings from the left and right hemisphere, 
respectively, are shown for a representative transgenic mouse overex-
pressing lamin B1 (top traces) or a WT control (bottom traces). Arrow-
heads mark interictal spikes. (B) Quantification of interictal spikes over 
24-hour recordings indicates the occurrence of spontaneous epilepti-
form activity in Lmnb1BAC mice specifically. n = 10 animals per genotyp-
ic group. (C) Histogram quantifying percentage of animals seizing after 
the administration of 30 mg/kg of PTZ. n = 9 animals per genotypic 
group. Values are expressed as means ± SEM. *P < 0.05.
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Figure 4
Lamin B1 overexpression results in aberrant myelin formation, axonal degeneration, and demyelination. Ultrastructural analysis was performed 
on pyramidal tracts of 12- and 24-month-old Lmnb1BAC and corresponding WT mice. (A and B) g ratio analyses at 12 and (C and D) 24 months, 
at which time demyelination is prominent in Lmnb1BAC mice. P < 0.05. (E) WT controls at 12 months. (F and G) Ultrastructural analyses revealed 
numerous aberrant structures, which included outfoldings, extensions, and invaginations originating from the myelin sheath at 12 months and 
(H) at 24 months. (I and J) Axonal disintegration and degradation of the entire axon-myelin unit was observed at a significantly higher level at 
12 months and (M and N) at 24 months compared with WT controls. (K and L) Hypermyelinated fibers and dying axons were also observed in 
Lmnb1BAC mice at 12 months of age. (O) Normal oligodendrocyte and (Q) normal compact myelin at 24 months of age in control animals. (P) 
Representative of frequent dying and degenerating oligodendrocytes in 24-month-old Lmnb1BAC mice. Dying oligodendrocytes correlate with 
increased (R) irregular and demyelinated fibers in 24-month-old Lmnb1BAC animals. (S and T) Quantification of approximately 150 to 200 axons 
for 12-month-old Lmnb1BAC mice exhibited significant axonal degeneration and aberrant myelin formations compared with WT controls. n = 3 
animals per genotype. Values are expressed as means ± SEM. **P < 0.01, ***P < 0.001. Scale bars: 2 μm.
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PLP-LMNB1Tg mice (Supplemental Figure 1). The neuropathology 
and age-dependent motor deficits observed in PLP-LMNB1Tg ani-
mals may more accurately reflect mechanisms related to degenera-
tion in ADLD. Consistent with the global overexpressing Lmnb1BAC 
mice, PLP-LMNB1Tg animals also exhibited spontaneous seizures 
(data not shown). Animals overexpressing lamin B1 specifically in 
neurons (CAM/tet-Lmnb1) and astrocytes (GFAP/tet-Lmnb1) showed 
no motor deficits on the balance beam and accelerated rotarod at 
12 months and no overt behavioral abnormalities beyond 1 year 
(Supplemental Figure 3, B and C, respectively). Together, these 
results indicate that oligodendrocytes are inherently more vulner-
able to the overexpression of lamin B1 than other cell types.
Lamin B1 overexpression results in significant decrease of the highly 
abundant myelin protein PLP. We used quantitative mass spectrom-
etry iTRAQ labeling to compare hindbrain protein levels from 
12-month-old Lmnb1BAC and WT mice. Out of 500 proteins iden-
tified at 95% confidence interval of high-quality scoring peptide 
candidates, only 4 proteins showed substantial changes (P < 0.05). 
The heterogeneous nuclear ribonucleoprotein (HNRNPN) and 
histone H4 (H4) were increased by 20% and 30%, respectively, 
while neurofilament medium polypeptide protein (NEFM) was 
reduced by 20%. Interestingly, PLP was reduced by 30% (Figure 
7A). Decreased Plp1 expression was confirmed by qRT-PCR (Figure 
7B). Mice overexpressing lamin B1 specifically in oligodendrocytes 
(PLP-LMNB1Tg) exhibited further reduction in PLP transcript levels 
(Figure 7C). However, mice overexpressing lamin B1 specifically in 
neurons (CAM/tet-Lmnb1) did not show any changes in Plp1 levels 
compared with WT controls (Supplemental Figure 3D).
In addition, we performed transcriptome analysis by identifying 
Pol II–binding sites on a genome-wide scale from oligodendro-
cytes purified from Lmnb1BAC and WT control mice. Pol II binding 
was changed on promoters of a wide variety of genes. However, 
Pol II binding validated proteomic changes, including identifying 
decreased Pol II binding to the Plp1 promoter in Lmnb1BAC mice 
compared with WT controls (Figure 7D). Together, these 2 inde-
pendent approaches suggest that lamin B1 overexpression results 
in altered gene expression and specifically suggest that a highly 
abundant myelin protein gene, Plp1, is reduced at the transcrip-
tional level. This lowered Plp1 transcription level serves as an entry 
point for studies aimed at understanding pathophysiology in 
ADLD. We hence sought to further examine how lamin B1 overex-
pression leads to altered PLP1 transcription.
Loss of binding occupancy of YY1 to Plp1 promoter. Alteration of 
gene transcription can result from many mechanisms, including 
changes in transcription factor binding and occupancy in the pro-
moter region of the affected gene. In an effort to identify potential 
factors that contribute to the altered gene regulation of Plp1, we 
performed quantitative ChIP using known transcription factor 
candidates of the Plp1 promoter from hindbrains of 12-month-
old Lmnb1BAC and WT mice. We identified YY1, a known transcrip-
Figure 5
Lamin B1 overexpression in oligodendrocytes results in progressive motor impairment and myelin deficits. (A) Representative Western blot for 
lamin B1, FLAG-tagged lamin B1, and α-tubulin in hemibrain lysates from transgenic mouse lines overexpressing lamin B1 selectively in oli-
godendrocytes, neurons, and astrocytes driven by cell-type–specific promoters (Plp1, Camk2a, and GFAP, respectively) vs. control mice at 12 
months of age (lanes are discontinuous). Dual color detection with IR fluorescence for antibody against lamin B1 (green) and antibody against 
FLAG-tagged lamin B1 (red; top panel). Individual detection against FLAG (second panel), lamin B1 (third panel), and α-tubulin (bottom panel). 
(B) Quantification of Western blots of total lamin B1 normalized to α-tubulin. (C) qRT-PCR of lamin B1 transcript levels normalized to GAPDH from 
corresponding cell-specific hemibrains at 12 months of age. Error bars represent mean ± SEM from 3–4 independent experiments. (D–F) Animals 
overexpressing lamin B1 selectively in oligodendrocytes (PLP-LMNB1Tg) exhibited progressive motor deficits on the accelerated rotarod and bal-
ance beam. (D) PLP-LMNB1Tg mice had shortened latency to fall on the accelerated rotarod and (E) exhibited increased latency to traverse an 
11-mm–wide balance beam with (F) hind limb slips. Values are expressed as means ± SEM, n = 10–12 per group. ***P < 0.001.
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tional activator of Plp1 (18), as binding and occupying the Plp1 
promoter significantly less in Lmnb1BAC hindbrains than in WT 
controls (Figure 8A). No differences were found in ChIP reactions 
performed by IgG antibody or real-time PCR for Plp1 3′ UTR, dem-
onstrating the specific changes of YY1 binding to the Plp1 promot-
er (Figure 8A). We next asked whether decreased binding of YY1 to 
the Plp1 promoter resulted from reduced YY1 levels. We measured 
total protein levels of YY1 in hindbrains of 12-month-old mice and 
found no difference among genotypes (Figure 8, B and C). Taken 
together, these results indicate that overexpression of lamin B1 
affects myelin-producing cells through the misregulation of Plp1 
gene expression, in part via the transcription factor YY1.
Discussion
Duplication of the gene encoding lamin B1 causes ADLD. Here, we 
demonstrate that overexpression of lamin B1 in mice recapitulates 
many key features of ADLD. Lmnb1BAC mice exhibit spontaneous 
seizures, cognitive impairments, and age-dependent motor deficits 
similar to what is observed in ADLD patients. Ultrastructural analy-
sis revealed aberrant myelin foldings eventually leading to myelin 
and axonal degeneration in Lmnb1BAC mice. Although lamin B1 is 
broadly expressed in Lmnb1BAC mice, we found that specific overex-
pression of lamin B1 in oligodendrocytes (PLP-LMNB1Tg mice) was 
sufficient to induce similar abnormalities, suggesting a cell-auton-
omous mechanism linking lamin B1 to myelin defects. Quantitative 
proteomic analysis of Lmnb1BAC mice revealed substantial reduction 
in PLP protein levels relative to WT controls (P < 0.05). Consistent 
with these results, we found that both RNA Pol II binding on the 
Plp1 promoter and transcript levels of Plp1 were downregulated in 
Lmnb1BAC animals. Finally, using quantitative ChIP assays, we dis-
covered that YY1, a transcriptional activator of Plp1, was found at 
markedly reduced levels at Plp1 promoters. Taken together, these 
data suggest that the effects of lamin B1 overexpression are mani-
fested, at least in part, through altered transcription of a gene 
known to play a key role in maintenance of the myelin sheath.
Although seizures have long been recognized to be part of the 
disease spectrum of MS, epileptiform activity is not a major fea-
ture in inherited leukodystrophies. One explanation may be that 
these are rare diseases with a general lack of EEG data in affected 
individuals. A more careful search for electrographic abnor-
malities is leading to an increase awareness of seizures in some 
leukodystrophies (22, 29). Among inherited leukodystrophies 
in children, 49% were noted to have epilepsy (30). The precise 
pathogenesis of epileptic seizures in inherited leukodystrophies 
is not well understood. Cognitive decline has been shown to cor-
relate with cortical pathological severity and seizures in MS (31). 
An increased risk of seizures may also be associated with ADLD; 
a possible mechanism could be damage to the brain parenchy-
ma leading to seizure susceptibility. Alternatively, the effects of 
demyelination on the cortex could cause cortical hyperexcitabil-
ity resulting from altered axonal signaling.
PMD is an X-linked demyelination disorder typically caused 
by duplications of PLP1. How duplication of PLP1 leads to PMD 
remains unclear. However, recent studies showed that much of 
the PLP being produced from the higher gene dosage fails to be 
incorporated into the myelin sheath in a mouse model of PMD 
duplication (32). Consistent with this finding, we found that 
overexpression of lamin B1 also results in substantial decrease 
of PLP. Disease characteristics of ADLD and PMD, while over-
lapping, are not identical, suggesting that pathophysiology of 
these diseases is not solely due to decreased PLP. Our observa-
tion that Plp1 transcript levels are reduced as early as 11 weeks 
(data not shown), while behavioral impairments and myelin 
defects are not seen until 1 year of age in Lmnb1BAC animals, fur-
ther suggests that PLP downregulation alone is insufficient to 
explain the ADLD-like phenotypes. Rather, PLP downregulation 
is likely to initiate a pathological myelin state that is exacerbated 
as animals age and trigger multiple mechanisms.
Considering that lamin B1 overexpression is likely to affect tran-
scriptional activity of a number of genes, ADLD is probably the 
consequence of misregulation of a subset of genes, including PLP, 
Figure 6
PLP-LMNB1Tg mice exhibit demyelination, aberrant myelin formation, 
and axonal degeneration. (A and B) PLP-LMNB1Tg animals exhibited 
demyelination compared with WT controls, quantified by g ratio of 
150–200 axons, P < 0.05. (C and D) PLP-LMNB1Tg animals showed 
aberrant myelin formation and axonal degeneration. (E and F) Demy-
elinating axons (e.g., arrow) and axons with normal myelin thickness 
(e.g., arrowhead) were frequently observed in PLP-LMNB1Tg mice (E) 
but not in WT controls (F). Myelin-axon structure also appeared irregu-
lar and nonuniform in PLP-LMNB1Tg mice compared with WT controls. 
n = 4 animals per genotype. Scale bars: 2 μm.
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which together bring about the features of ADLD. Consistent with 
this hypothesis, our transcriptome analysis points to several other 
gene candidates: for instance, we found that superoxide dismutase 
1 (Sod1), an important regulator of superoxide radicals, was tran-
scriptionally downregulated while the oligodendrocyte lineage 
transcription factor 2 (Olig2), a transcription factor known to be 
important for oligodendrocyte development, was upregulated 
upon lamin B1 overexpression (Figure 7D).
The precise mechanism through which lamin B1 overexpres-
sion leads to a specific downregulation of PLP is not yet known. 
However, nuclear lamins are known to regulate gene expression, 
in part through interactions with chromatin and repression of 
transcription. Previous studies have shown that nuclear lamins 
interact with DNA, histones, transcription factors, and chro-
matin proteins. Direct interaction of DNA with nuclear lamins 
causes downregulation of genes locally (33–35). Moreover, deple-
tion of lamin B1 in Drosophila led to an upregulation of lamina-
associated genes (36), specifically showing a direct role for lamin 
B1 in gene repression. We found a reduction in YY1 occupancy 
at Plp1 promoters in lamin B1–overexpressing animals with no 
change to the overall total protein level of YY1. It is therefore 
plausible that overexpression of lamin B1 pulls the Plp1 promoter 
region into a heterochromatin-like state and reduces accessibil-
ity of these regions to the YY1 transcription factor. Additionally, 
YY1 has previously been proposed to facilitate the attachment of 
the PLP1 promoter region to transcriptionally active domains of 
the nuclear matrix (18). Our observation that histone H4 levels 
were increased upon lamin B1 overexpression also supports the 
idea that lamin B1 overexpression leads to repressed transcrip-
tion in specific genomic regions.
Together, these findings implicate lamin B1 as a modulator of 
myelin and genes involved in premature myelin breakdown, par-
Figure 7
Lamin B1 overexpression results in the decrease of the highly abundant myelin protein PLP. (A) Quantitative mass spectrometry iTRAQ labeling of 
hindbrains from 12-month-old Lmnb1BAC mice and WT mice identified PLP at 95% confidence interval of high-quality scoring peptide candidates 
to be 30% downregulated in Lmnb1BAC animals compared with WT controls. (B) This finding was validated by qRT-PCR. (C) Mice overexpressing 
lamin B1 specifically in oligodendrocytes (PLP-LMNB1Tg) exhibited a further reduction in Plp1 transcript levels. Values are expressed as means 
± SEM. n = 3 per group. **P < 0.01; ***P < 0.001. (D) Transcriptome analysis performed on purified oligodendrocytes validated proteomic changes 
including decreased Pol II binding to the Plp1 promoter in Lmnb1BAC mice compared with WT controls. Lamin B1 also regulates additional genes. 
x axis defined as M: log differential-expression ratio (log fold change); y axis defined as A: average log intensity (reads per kb of gene length) from 
oligodendrocytes between Lmnb1BAC mice and WT controls.
Figure 8
Lamin B1 overexpression results in reduced binding occupancy of YY1 to Plp1 promoter. (A) Quantitative ChIP coupled to PCR revealed a reduc-
tion in YY1 binding to the Plp1 promoter in hindbrains from 12-month-old Lmnb1BAC mice compared with WT controls normalized to 2% input. 
Primers were designed to amplify 150–200 bp containing either a consensus YY1-binding site or 3′ UTR. 3′ UTR and IgG were used as controls. 
(B) Representative blot of YY1 total protein levels normalized to α-tubulin in hindbrains of 12-month-old Lmnb1BAC and WT mice. (C) Quantifica-
tion of YY1 protein level relative to α-tubulin was found not to be markedly different between Lmnb1BAC and WT mice. n = 4 per group of at least 
2 independent experiments. P > 0.05.
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ticularly in the aging process. Lamin B1 and its myelin-specific 
regulatory targets are therefore potential therapeutic avenues for 
remyelination in various demyelinating disorders.
In summary, we provide a valid murine model of ADLD that 
recapitulates human ADLD. Collectively, our results implicate 
an important role for lamin B1 in modulation of genes involved 
in normal myelin regulation, which may provide further elucida-
tion of the molecular mechanisms that underlie a spectrum of 
myelin-related disorders including leukodystrophies, laminopa-
thies, and multiple sclerosis. Ultimately, there is hope that such 
insights may provide novel potential therapeutic strategies for 
disorders of myelin.
Methods
Animals and generation of transgenic mice
All animals were housed in cages grouped by sex and provided with food 
and water ad libitum. Animals were housed under specific pathogenic–free 
conditions with a 12-hour light/12-hour dark cycle maintained at 23°C. 
Behavioral testing occurred between 8 am and 5 pm during the light cycle. 
Experiments were blind to mouse genotype and treatment during testing.
Lmnb1BAC. For transgenesis, a large genomic insert (177.20 kb) containing 
the entire mouse Lmnb1 locus and cloned into the BAC vector pBACe3.6 
was isolated from a mouse BAC genomic library (BAC RP23-460J18 clone; 
RPCI library, C57BL/6J). Purified BAC DNA was used for microinjection 
into the pronuclei of fertilized oocytes of C57BL/6J mice and was main-
tained on a C57BL/6J genetic background.
PLP-LMNB1Tg. We generated transgenic mice encoding a FLAG-tagged 
human lamin B1 cDNA, which was cloned into a PLP promoter-exon 
expression cassette as previously described (37). The purified construct was 
then used for microinjection into the pronuclei of fertilized oocytes of FVB 
mice and was maintained on an FVB genetic background.
CAM/tet-Lmnb1 and GFAP/tet-Lmnb1. Double-transgenic mice (CAM/tet-
Lmnb1 and GFAP/tet-Lmnb1) were generated by crossing Camk2a tTA and 
GFAP-tTA mice (38, 39), respectively (B6/CBA genetic background), to a 
FLAG-tagged tetracycline-responsive element (TRE)-Lmnb1 mice (FVB). 
Both lines were maintained separately and crossed to generate F1 mice 
hemizygous for each transgene.
Behavioral testing
MWM. Lmnb1BAC and WT mice were tested using the MWM, as described 
(40). In brief, over a number of trials, animals were trained to find a 
hidden platform in the MWM using spatial cues. Memory was tested 
24 hours afterwards by a probe trial in which the hidden platform was 
removed and the amount of time and number of platform area crossings 
were quantified.
PA. The PA test was used as previously described (41). A light/dark 
chamber with a sliding trap door separating the 2 chambers was used. 
Briefly, animals were allowed to acclimate for 15 seconds in the light com-
partment. Once mice stepped through into the dark compartment they 
received a shock of 0.3 mA for a maximum of 2 seconds. The latency to 
enter the dark compartment was recorded. The memory-retention test was 
performed 24 hours later without shock. A maximum retention latency of 
400 seconds was given to mice that did not enter the dark compartment 
before that time (Gemini Avoidance System).
Accelerated rotarod and balance beam. To assess motor coordination and bal-
ance, animals were tested on the accelerated rotarod and balance beams 
as previously described (42). Animals were tested on 42-cm–long Plexiglas 
beams (5 mm wide and 11 mm wide). Latency to traverse each beam and 
hind limb slips were recorded. The accelerated rotarod was accelerated from 
4 to 40 rpm over a period of 270 seconds, and the time spent on the drum 
was recorded for each mouse. Animals were tested 1 trial per day over 8 trials 
unless otherwise stated.
Video-EEG monitoring
EEG recordings were performed as previously described (43). Briefly, Tef-
lon-coated silver wires were implanted into the subdural space over the 
left and right parietal cortices, and the left frontal cortex was used as a 
reference. EEG activity was recorded in freely moving mice with Harmonie 
5.0b software (Stellate). The number of abnormal epileptiform spikes 
(sharp-wave discharges with amplitude exceeding 6 times the mean EEG 
amplitude and lasting 20–70 ms) was automatically detected by the Got-
man spike detectors (Harmonie; Stellate) over 24 hours of recording. The 
latency to seize and the number of seizures were visually quantified.
PTZ challenge
PTZ (Sigma-Aldrich) was dissolved in PBS. A dose of 30 mg/kg was admin-
istered intraperitoneally.
Transmission electron microscopy
Toluidine blue staining and g ratio analysis. 12-month-old animals were deeply 
anesthetized and intracardially perfused with 2% paraformaldehyde and 
1.25% glutaraldehyde in 0.1 M sodium cacodylate buffer, pH 7.4 (n = 3 per 
group for Lmnb1BAC mice, n = 4 per group for PLP-LMNB1Tg mice). Brains were 
postfixed in 2% osmium tetroxide in the same buffer, en block stained in 2% 
aqueous uranyl acetate, dehydrated, infiltrated, and embedded in LX-112 
resin (Ladd Research Industries). For light microscopy,1.5 μm semi-thin sec-
tions of pyramidal tracts at the level of the pons near decussation were cut 
and stained with 0.5% Toluidine blue O in a Borax solution. Experiments were 
performed as previously described with the above modifications (44). The g 
ratio of axons in the area of interest was obtained as a ratio of the diameter of 
an axon over the diameter of axon plus associated myelin sheath as previously 
described (45). Approximately 150 to 200 axons for each group of 4 animals 
were used. Digitized and calibrated images were analyzed using ImageJ (NIH).
Expression analysis
qRT–PCR was performed by the ΔΔCt method normalized to GAPDH con-
trol using ABI Sybr Green/ROX gene-specific primers. Data were collected 
and analyzed with an ABI 7900HT machine and software. Total RNA was 
isolated from whole brains of 11-week-old, and 12-month-old mice (n ≥ 3/
group) using an RNeasy isolation kit (QIAGEN). Total RNA was reverse 
transcribed using SuperScriptII Reverse Transcriptase according to the 
manufacturer’s instructions (Invitrogen).
Primer sequences for GAPDH (46) and Plp1 (47) are as follows: Lmnb1 
(spanning exons 2–3); forward sequence, 5′-CAGATTGCCCAGC-
TAGAAGC-3′; reverse sequence, 5′-CATTGATCTCCTCTTCATAC-3′.
Brain lysate and Western blotting
Brain lysates and Western blotting were performed as previously described 
(48). In brief, flash-frozen hemibrains were homogenized in RIPA buffer 
(20 mM Tris, 150 mM NaCl, 0.1% SDS, 0.5% deoxycholic acid, 1% Nonidet 
P-40, pH 7.4) with protease inhibitors (PI) (Sigma-Aldrich). Supernatants 
were supplemented with 1% final SDS and 100 mM DTT, boiled, loaded 
on 7.5% or 10% SDS-PAGE gels and transferred to PVDF membrane. The 
primary antibodies YY1 (1:500, sc-1703; Santa Cruz Biotechnology Inc.), 
lamin B1 (1:50, sc-6216; Santa Cruz Biotechnology Inc.), and α-tubulin 
(1:5,000, Sigma-Aldrich T9026) were incubated overnight, followed by spe-
cies-matched, infrared-labeled (IR-labeled) secondary anti-mouse or anti-
rabbit antibodies (dilution 1:5,000; Li-Cor Biosciences). Blot membranes 
were imaged using Odyssey IR Imaging system (Li-Cor Biosciences).
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Statistics
Comparisons of different groups (between genotypes) were performed on 
experiments requiring nonrepeated trials using 2-tailed independent t tests 
and regression analysis. Repeated measures t test with between-subject factor 
for genotype and repeated measures for training were performed on experi-
ments for behavioral tests requiring repeated trials. There were no interactions 
observed between genotype and training. If there was no effect from repeated 
training, trials were collapsed, and a 2-tailed t test was performed. Paired t test 
was performed when animals were subjected to different behavioral condi-
tions in a given paradigm. All t tests and P values presented were performed 
from 2-tailed tests. All data are presented as mean ± SEM. P < 0.05 was consid-
ered to be statistically significant. The Huynh-Feldt adjustment was used in 
correcting for the violation of sphericity when necessary to adjust nonuniform 
variance across days or groups. Data were analyzed with IBM SPSS 20.0.
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Immunohistochemistry
Immunohistochemical analysis was performed as described previ-
ously (48). Briefly, hemibrains were fixed in 4% paraformaldehyde for 
24 hours, cryoprotected in 20% sucrose in 0.1 m phosphate buffer for 
an additional 24 hours at 4°C, frozen, and stored at –80°C until use. 
Free-floating 30-μm serial sections were processed with primary antisera 
against GFAP (1:1000, Millipore ab5804) and Iba1 (1:1000, Wako Chem-
ical, 019-19741). Detection of immunoreactivity was performed using 
the Vectastain Elite kit (Vector Laboratories) according to the manufac-
turer’s protocol, and sections were developed in ImmPACT DAB (Vector 
Laboratories) for visualization. Sections were mounted and dehydrated 
in graded alcohols and xylene. Coverslips were affixed with DPX (Elec-
tron Microscopy Sciences). Quantification of GFAP and Iba1 immuno-
reactivity were performed using NIH ImageJ software. Particle numbers 
were quantified with the “analyze particles” function in “threshold and 
measure” functions with the scale standardized to the scale bar and set 
globally. Experiments used n = 3 per group for a total of 7–10 sections per 
animal and 2 fields of view per section.
Quantitative ChIP PCR
ChIP assays were performed with the SimpleChIP-Enzymatic Chromatin 
IP Kit (Cell Signaling) according to the manufacturer’s instructions. Brain 
lysates were prepared in PBS with PIs. Samples of input DNA were pre-
pared in the same manner. Cell lysates were sonicated and immunopre-
cipitated with normal IgG or specific antibody against YY1 (sc-1703; Santa 
Cruz Biotechnology Inc.). The DNA thus obtained was analyzed by real-
time PCR with a set of primers directed against the Plp1 promoter region 
containing the YY1 consensus site (18). Plp1 3′ UTR was used as a nega-
tive control. PCR reactions were performed in triplicate in the presence of 
SYBR Green (Roche Diagnostics).
iTRAQ analysis
iTRAQ analysis was performed as previously described (49). Isolated hind-
brain protein powders were dissolved in 50 μl of iTRAQ dissolution buffer 
(20-fold diluted, final concentration = 25 mM, pH 8.5), and protein con-
centrations were measured using a protein assay kit (Bio-Rad). 40 μg of 
protein for each sample was labeled for each iTRAQ experiment (Applied 
Biosystems) following the manufacturer’s instructions. The final mixture 
of labeled samples was desalted and purified using an MCX cartridge 
(Mixed-mode Cation Exchange, Oasis solid phase extraction, 30 μm, 
3 cc, 60 mg). They were then subjected to HPLC fractionation and mass 
spectrometry analysis.
Transcriptome analysis
OPC purification. Purification of oligodendrocyte progenitor cells (OPCs) 
from P7-8 Lmnb1BAC mice or WT was carried out as described previously (50). 
In brief, OPCs were cultured in proliferation medium (+PDGF10 ng/ml 
+NT3, 1 ng/ml) for 6 days followed by differentiation medium (40 ng/ml 
triiodothyronine) for 4 days. OPCs were fixed with 1% formaldehyde solu-
tion and frozen immediately at –80°C before the ChIP-Seq using the RNA 
polymerase II antibody (Active Motif).
Data analysis. Analysis of Pol II–binding sites on a genome-wide scale 
from oligodendrocytes purified from Lmnb1BAC and WT control mice were 
normalized by the total number of reads between the transgenic and the 
control samples. For each mouse gene defined by Ensembl, including 2-kb 
upstream and 6-kb downstream regions, we counted the number of reads 
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